CAUTION–Investigational Device. Limited by United States Law to Investigational Use.
Corvia Medical, Inc., is dedicated to revolutionizing the treatment of heart failure with first-in-class structural heart devices. The company has developed the world’s first transcatheter device designed to treat heart failure with preserved (HFpEF) or mid-range (HFmrEF) ejection fraction, previously known as diastolic heart failure (DHF). The innovative InterAtrial Shunt Device (IASD®) is clinically proven to reduce elevated left atrial pressure (LAp), which is the main cause of heart failure symptoms.
Corvia Atrial Shunt System receives NUB 1 reimbursement status in Germany for 2021.
Das Corvia Atrial Shunt System erhält den NUB Status 1 für 2021 in Deutschland.